FIELD: biotechnology.
SUBSTANCE: antibody that specifically binds to human factor D is proposed. Also a method of treating a disease or disorder mediated by an alternative complement pathway by exposing a patient to an anti-factor D antibody is provided. Also a method of reducing the activity of an alternative complement pathway in a patient is provided.
EFFECT: invention can be used therapeutically to block the activity of the alternative complement pathway.
13 cl, 30 dwg, 1 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| COMPOSITION AND METHOD FOR TREATING A COMPLEMENT-MEDIATED DISEASE | 2016 |
|
RU2727411C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| NOVEL MONOCLONAL ANTIBODIES TO LAM AND PIM6/LAM FOR DIAGNOSING AND TREATING INFECTIONS CAUSED BY MYCOBACTERIUM TUBERCULOSIS | 2017 |
|
RU2732502C2 |
| METHODS FOR TREATMENT OF DANON'S DISEASE AND OTHER AUTOPHAGY DISORDERS | 2017 |
|
RU2777571C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| PAIN TREATMENT | 2009 |
|
RU2712166C2 |
